A Review on the Synthesis and Anti-cancer Activity of 2-substituted Quinolines

Author(s): Kaalin Gopaul, Suhas A. Shintre, Neil A. Koorbanally

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 15 , Issue 5 , 2015

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Quinolines substituted at C-2 on the quinoline scaffold have shown interesting anticancer activity in a number of anticancer assays such as breast (MCF-7, MDA-MB 231), human cervical epithelioid (HeLa), oral squamous cell carcinoma (SAS), human stomach adenocarcinoma (AGS, MKN45), hepatocellular (SKHep, HepG-2, Hep-3B), prostate (PC-3, DU145), lung (A549, H-460), gastric (HGC, MNK-74), leukemia (K562, U937, REH, NALM6, CEM/ADR 5000), colon (Colo-205, HCT 116, SW620, Caco-2, HT29), neuroblastoma (IMR32), CNS (SF-268), oesophageal (EAC) and melanoma (A-375). They have been synthesised by a number of strategies starting with isatin, anilines, nitrobenzenes and benzamides and some even with cyclohexanone and cyclohexa-1,3-diones with ammonium acetate. Many of the synthetic strategies employ the derivatisation of quinoline precursors itself. We review here the synthesis of 145 bioactive anticancer quinolines substituted at the 2-position and their anticancer activity.

Keywords: Anti-cancer, quinoline, 2-substituted.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Published on: 14 May, 2015
Page: [631 - 646]
Pages: 16
DOI: 10.2174/1871520615666141216125446
Price: $65

Article Metrics

PDF: 47